161 related articles for article (PubMed ID: 18296119)
1. The neurokinin 1 receptor: a potential new target for anti-platelet therapy?
Jones S; Gibbins JM
Curr Opin Pharmacol; 2008 Apr; 8(2):114-9. PubMed ID: 18296119
[TBL] [Abstract][Full Text] [Related]
2. Tweaking the gain on platelet regulation: the tachykinin connection.
Gibbins JM
Atherosclerosis; 2009 Sep; 206(1):1-7. PubMed ID: 19150714
[TBL] [Abstract][Full Text] [Related]
3. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
Savi P; Bernat A; Lalé A; Roque C; Zamboni G; Herbert JM
Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
[TBL] [Abstract][Full Text] [Related]
4. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
Nurden AT
Haemostasis; 1996 Oct; 26 Suppl 4():78-88. PubMed ID: 8979114
[TBL] [Abstract][Full Text] [Related]
5. Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation.
Jones S; Tucker KL; Sage T; Kaiser WJ; Barrett NE; Lowry PJ; Zimmer A; Hunt SP; Emerson M; Gibbins JM
Blood; 2008 Jan; 111(2):605-12. PubMed ID: 17895403
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological control of platelet function.
Clutton P; Folts JD; Freedman JE
Pharmacol Res; 2001 Oct; 44(4):255-64. PubMed ID: 11592859
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of platelet activation and development of antiplatelet agents].
Cazenave JP; Gachet C; Lanza F
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
[TBL] [Abstract][Full Text] [Related]
10. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
Bright JM; Dowers K; Powers BE
Vet Ther; 2003; 4(1):35-46. PubMed ID: 12756634
[TBL] [Abstract][Full Text] [Related]
11. Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions.
Ferguson JJ; Zaqqa M
Drugs; 1999 Dec; 58(6):965-82. PubMed ID: 10651385
[TBL] [Abstract][Full Text] [Related]
12. Targeting platelet G-protein coupled receptors (GPCRs): looking beyond conventional GPCR antagonism.
Dowal L; Flaumenhaft R
Curr Vasc Pharmacol; 2010 Mar; 8(2):140-54. PubMed ID: 19485898
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA.
Wu J; Zhu H; Yang G; He J; Wang Y; Zhao S; Zhang X; Gui L; Zhao M; Peng S
Int J Nanomedicine; 2018; 13():1139-1158. PubMed ID: 29520141
[TBL] [Abstract][Full Text] [Related]
14. Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation.
Jia YM; Ge PX; Zhou H; Ji JZ; Tai T; Gu TT; Zhu T; Li YF; Mi QY; Huang BB; Xie HG
Biomed Pharmacother; 2019 Jul; 115():108906. PubMed ID: 31060007
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
16. Future innovations in anti-platelet therapies.
Barrett NE; Holbrook L; Jones S; Kaiser WJ; Moraes LA; Rana R; Sage T; Stanley RG; Tucker KL; Wright B; Gibbins JM
Br J Pharmacol; 2008 Jul; 154(5):918-39. PubMed ID: 18587441
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa antagonists--from bench to practice.
Casserly IP; Topol EJ
Cell Mol Life Sci; 2002 Mar; 59(3):478-500. PubMed ID: 11964126
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet drugs. A comparative review.
Schrör K
Drugs; 1995 Jul; 50(1):7-28. PubMed ID: 7588091
[TBL] [Abstract][Full Text] [Related]
19. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
20. Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents.
Goto S
Curr Vasc Pharmacol; 2004 Jan; 2(1):23-32. PubMed ID: 15320830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
